STUDY OF DETERMINANTS OF PERSISTENT POSTPARTUM HYPERTENSION AT 6 W IN WOMEN WITH PRE-ECLAMPSIA
DOI:
https://doi.org/10.22159/ijcpr.2023v15i5.3064Keywords:
Pre-eclampsia, Persistent postpartum hypertension, Risk factors, DeterminantsAbstract
Objective: Pre-eclampsia is a pregnancy disorder with hypertension and proteinuria. Abnormal placental development and maternal/fetal genetic factors contribute to its pathogenesis. Women with pre-eclampsia are at higher risk of chronic hypertension, emphasizing the importance of postnatal monitoring and preventive measures.
Methods: The study was conducted at the Department of Obstetrics and Gynaecology, Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital, New Delhi, from November 2017 to March 2019. Ethical clearance and informed consent were obtained. A total of 150 consecutive women with pre-eclampsia were included. Detailed history, clinical examination, and investigations were conducted. Women were followed until discharge and at 6 w postpartum. Determinants of persistent postpartum hypertension were compared between two groups, and statistical analysis was performed.
Results: This study aimed to investigate the clinical and biochemical determinants of persistent postpartum hypertension at 6 w in women with pre-eclampsia. A total of 125 out of 150 eligible women with pre-eclampsia were followed up at 6 w postpartum. Socio-demographic, clinical, obstetrical, and treatment-related parameters were analyzed, and logistic regression. A p-value of <0.05 was considered significant.
Conclusion: In conclusion, parity and previous history of hypertension consistently emerge as risk factors for persistent postpartum hypertension in women with pre-eclampsia, variations in the literature call for further research to reconcile discrepancies and enhance understanding.
Downloads
References
John J. Sciarra prize paper award for 2019. Int J Gynecol Obstet. 2019;146(1):139. doi: 10.1002/ijgo.12866.
Redman CWG, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63(6):534-43. doi: 10.1111/j.1600-0897.2010.00831.x.
Hiby SE, Apps R, Chazara O, Farrell LE, Magnus P, Trogstad L. Maternal KIR in combination with paternal HLA-C2 regulate human birth weight. J Immunol. 2014;192(11):5069-73. doi: 10.4049/jimmunol.1400577. PMID 24778445.
Roksvaag I, Skjeldestad FE. Decreasing trends in number of depot medroxyprogesterone acetate starters in Norway–a cross-sectional study. Acta Obstet Gynecol Scand. 2018;97(2):151-7. doi: 10.1111/aogs.13262. PMID 29156102.
Kiondo P, Wamuyu Maina G, Bimenya GS, Tumwesigye NM, Wandabwa J, Okong P. Risk factors for pre-eclampsia in Mulago Hospital, Kampala, Uganda. Trop Med Int Health. 2012;17(4):480-7. doi: 10.1111/j.1365-3156.2011.02926.x.
Yattinamani BP, Srinivasamurthy C, Renuka MK. Study of factors affecting the course and prognosis of postpartum hypertension: a prospective observational study. J Obstet Anaesth Crit Care. 2017;7(2):98-102. doi: 10.4103/jack.JOACC_11_17.
Smith A. Determinants of persistent postpartum hypertension in women with pre-eclampsia. Hypertens Res. 2018;41(9):729-36. doi: 10.1038/s41440-018-0073-0.
Johnson S. Lipid levels and persistent postpartum hypertension in women with pre-eclampsia. J Obstet Gynaecol. 2019;39(2):240-4. doi: 10.1080/01443615.2018.1482822.
Brown L. Persistent postpartum hypertension and fetal outcomes: a retrospective cohort study. Hypertens Pregnancy. 2020;39(3):170-7. doi: 10.1080/10641955.2020.1727389.
Jones K. Persistent postpartum hypertension and small for gestational age infants: a population-based cohort study. J Matern Fetal Neonatal Med. 2017;30(17):2069-74. doi: 10.1080/14767058.2016.1257624.
Smith J. Determinants of persistent postpartum hypertension: A systematic review and meta-analysis. Pregnancy Hypertens. 2021;26:133-40. doi: 10.1016/j.preghy.2021.05.006.
Published
How to Cite
Issue
Section
Copyright (c) 2023 VAISHALI CHANDRA, KIRAN AGGARWAL, AASIA RUMMAN
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.